Letter to the editors quency in Taiwanese patients was estimated from 64 unrelated non-diabetic Taiwanese subjects. No linkage was found under two diagnostic schemes by defining overt diabetes as affected or by defining both overt diabetes and impaired glucose tolerance as affected.
Incidence of IDDM in southern Europe
Dear Sir, Recently, in a very interesting paper, Roglic et al. [1] reported the incidence of insulin-dependent diabetes mellitus (IDDM) in Zagreb, Croatia. The prospective study, which took place during 1988-1992, using the capture-recapture method, showed an annual incidence rate over the 5-year period ranging from 5.6 to 6.6/100,000. The incidence peaked in the 10-14 year age group (12.4/100,000) while it remained stable over 24 years of age. The rates in the 15-30 years age group were close to 8/100,000. The authors concluded that: 1) childhood incidence of IDDM in Zagreb appears to be low and is similar to that of both southern European populations and those Of Slavic origin; 2) the peak, occurring in the 10-14 year age group, has also been reported for many other populations with very different rates; 3) rates for the 15-30 year age group were close to those found in some Italian areas (Turin and its province and Lombardy). Regretfully, the authors did not consider a previous study carried out in Italy (Sardinia) by our group, using essentially the same approach, which was the first standardised study to demonstrate that the incidence of IDDM in Sardinia was much higher than expected in a southern European region. During 1989-1990 [2] we were able to show in Sardinia (ascertainment probability of 92.8 %) a standardised incidence rate for people aged 0-29 years of 24.3/100,000 (0-14 years: 30/100,000; 15-29 years: 18.7/100,000) with a plateau of incidence rate at 5-14 years (5-9 years: 32.0/100,000 and 10-14 years: 32.8/100,000). Male/female ratios in the 0-29 and 0-14 years age groups were 1.55 and 1.25, respectively, with the highest ratio, 3.38, in the 25-29 year age group and the lowest, 1~14, in the 0-4 years group. Therefore, these data, coming from an area at a very high risk for IDDM, confirm the earlier peaking of IDDM also described in the four Italian regions included in the EURODIAB ACE network [3] Corresponding author: Dr . EURODIAB ACE data confirm this trend particularly in areas with high incidence rates such as Finland, Sardinia and Norway; the opposite trend on the other hand is observed in certain areas with low incidence rates such as Israel, Poland and Rumania [2] . Recent data collected by some EURODIAB ACE centres extending their age range up to 29 years have shown a pronounced excess of males but only for populations with medium or high background risk levels. Sex trends resulting from the EURODIAB ACE data concerning childhood IDDM seem to be more pronounced at higher age levels; this is one of the reasons why the EURODIAB ACE steering committee decided to set up a new multicentre European substudy on IDDM with onset in young adulthood (15-29 years) whose main aim is to better define the traditionally "heterogeneous" group of late-onset IDDM patients. Is human insulin without effect in the diabetic rat?
Dear Sir, It was with great interest that I read the paper by Soulis-Liparota et al. [1] , not only because it contains fine experimental work but also because I wonder if they had the same experience as I had recently. Blood glucose levels in their rats were above 30 mmol/1 despite treatment with 2 IU ultralente insulin. In a paper by Rasch [2] a similar insulin dose kept the blood glucose levels below 20 mmol/1. I would like the authors' opinion as to whether they think the type of insulin given had any effect on blood glucose level. I have recently found it impossible to purchase non-human insulin. In the work by Rasch [2] the most efficient insulin was bovine ultralente (Novo Nordisk, Copenhagen, Denmark). I used this insulin for maintaining a blood glucose level of around 20 mmol/1 (Fig. 1) . Diabetes meUitus was induced with an intraperitoneal injection of streptozotocin (90 mg/kg) in 24 male Sprague-Dawley rats (weight 140 g). Up to a diabetes duration of 33 days their blood glucose level was kept at 19 mmol/1 with a mean dose of one IU of bovine insulin given once a day. Thereafter, 18 animals were changed from bovine to human insulin (Ultratard HM 40 IU/ 20 --ml; Novo Nordisk). Despite successively increasing the insulin dose to 15 IU per day it was not possible to lower the blood glucose levels below 22 mmol/1. In contrast the blood glucose level in the six bovine-insulin-treated rats was maintained with a dose of 2 IU per day. The experiment leads to the following questions: is it possible to purchase non-human insulin? Is the human insulin without effect in the rat?
Yours sincerely, O. Torffvit
